APA highlights: Treatment trials in psychiatry
June 22, 2016…s MADRS score < 10. No serious adverse effects were reported. A prior proof-of-concept open-label study of oral ketamine (0.5 mg/kg) for 28 days reported significant improvements in depression by day 14 and in anxiety by day 3 in patients receiving hospice care (Irwin et al. J Palliat Med 2013;16:958-965). Back to top Anxiety disorders Panic disorder: An open-label study of clonazepam or paroxetine has found that long-term treatment does not preve…